Drug Discovery
ByCan Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Could Amgen’s 340B Pricing Practices Face Legal and Market Scrutiny?
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…
Is Novo Nordisk Positioning Cell-Based Therapies as the Future of Diabetes Care?
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech Aspect Biosystems, intensifying…
Is Novo Nordisk Facing Legal Scrutiny Over Diabetes Drug Market Conduct?
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the U.S., filed by…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for CC-1234, its next-generation…
Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…
